Friday 29 December 2017

An article published in “Neumosur.net” using our “CF-Blue Apoptosis Detection Kit” by our customers from the Center for Biomedical Research in Respiratory Diseases Network (CIBERES), Hospital Universitario Virgen del Rocío de Sevilla, Spain, in the analysis of CELLULAR ORIGIN OF CIRCULATING MICRO-PARTICLES IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE AND CANCER. Congrats and Thanks.


Summary:
Microparticles (MPs) are extracellular vesicles considered to be powerful cellular effectors. They are present in healthy individuals and are elevated in disease states such as diseases inflammatory, neoplastic and thrombosis. The relationship between venous thromboembolic disease (VTE) and cancer is well established It is thought that MPs would be a pathogenic connection between both entities. If confirmed, they could be used as biomarkers.
Our objective was to characterize the MPs in both pathologies according to their cellular origin (cellular, endothelial, platelet, leukocyte and those that exhibited mucin on its surface 1). Functional parameters were also studied such as dimer D (DD) and soluble P-selectin (sPS).
We considered 96 patients with idiopathic VTE and 85 with advanced neoplasms of lung, gastric or pancreas. To all of them underwent a clinical follow-up of two years in which those who were excluded from the study were excluded diagnosed with cancer in the ETV group or who developed thrombosis in the group of neoplastic patients. Finally, 82 patients with VTE and 68 with cancer were analyzed.
In our results we found that the total MPs and the MPs of platelet origin differentiated both groups of patients. In addition, significantly higher numbers of DD and sPS were determined (p <0.001) in the group of ETV. The differences found between both groups, taking into account the origin of the MPs, could be caused by the prothrombotic characteristics of the neoplastic group and the sequestration thereof within the clots assets in the ETV group.

Reference:

Products link:

CF-Blue Apoptosis Detection Kit

An article published in “Injury, International Journal of the Care of the Injured” using our PerCP-Cyanine5.5 Mouse Anti-Human CD45, clone D3/9 by our customers from the  National Institute of Traumatology and Orthopedics, Rio de Janeiro, Brazil, in the analysis of how Bone intramedullary reaming grafts the fracture site with CD146+ skeletal progenitors and downmodulates the inflammatory environment. Congrats and Thanks.


Summary:
Femoral shaft fractures generally occur in young adults following a high-energy trauma and are prone to delayed union/non-union. Novel therapies to stimulate bone regeneration will have to mimic some of the aspects of the biology of fracture healing; however, which are these aspects is unclear. Locked intramedullary nailing is the current treatment of choice for the stabilisation of femur shaft fractures, and it is associated with accelerated healing and increased union rates. These benefits were partially attributed to the reaming procedure, which, regardless of significantly destroying the haematoma, stimulates the healing response. To better understand how reaming influences healing, we evaluated the viability of the nucleated cell fraction and the frequency of CD146+skeletal progenitors, which contain multipotent cells, in the post-reaming haematoma. We also screened the concentrations of inflammatory mediators and growth factors in the fracture site after reaming compared with those in the original haematoma.

 

(A, B) Representative flow cytometry analysis of the CD45/CD31/CD146+ skeletal cell population in a representative pre- and post-reaming haematoma. Analyses were performed in cells gated subsequently in R1, R2, R3, and R4.

Reference:


Product link:

PerCP-Cyanine5.5 Mouse Anti-Human CD45, clone D3/9

Tuesday 26 December 2017

An article published this year in “Oncotarget” using one of our products, “PE Apoptosis Detection Kit”, by our customers from BioCruces Health Research Institute, Bizkaia, Spain, in the analysis of how Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells. Congrats and Thanks.
 

Summay:
Podocalyxin (PCLP1) is a CD34-related sialomucin expressed by some normal cells and a variety of malignant tumors, including leukemia, and associated with the most aggressive cancers and poor clinical outcome. PCLP1 increases breast tumor growth, migration and invasion; however, its role in hematologic malignancies still remains undetermined. The purpose of this study was to investigate the expression and function of PCLP1 in mature B-cell lymphoma cells. We found that overexpression of PCLP1 significantly increases proliferation, cell-to-cell interaction, clonogenicity, and migration of B-cell lymphoma cells. Furthermore, PCLP1 overexpression results in higher resistance to death induced by dexamethasone, reactive oxygen species and type II anti-CD20 monoclonal antibody obinutuzumab. Strikingly, enforced expression of PCLP1 enhances lipid droplet formation as well as pentose phosphate pathway and glutamine dependence, indicative of metabolic reprogramming necessary to support the abnormal proliferation rate of tumor cells. Flow cytometry analysis revealed augmented levels of PCLP1 in malignant cells from some patients with mature B-cell lymphoma compared to their normal B-cell counterparts. In summary, our results demonstrate that PCLP1 contributes to proliferation and survival of mature B-cell lymphoma cells, suggesting that PCLP1 may promote lymphomagenesis and represents a therapeutic target for the treatment of B-cell lymphomas.


A) Raji-Ctrl and Raji-PCLP1 cells were treated with increasing concentrations of vehicle or dexamethasone for 72 hours and cell death was analyzed after Annexin V-PE/7´AAD staining by flow cytometry. The graph on the left shows the mean percentages ± SD of total specific cell death (including early apoptosis, late apoptosis and necrotic cells) from six independent experiments after subtracting the spontaneous cell death (vehicle). The percentage of specific cell death was calculated as follows: [(% lysis of target cell – % spontaneous cell death)/(100% – % spontaneous cell death)] × 100. Representative dot plots showing Annexin V/7AAD staining in cells treated with vehicle or 1000 µM dexamethasone are shown (right). As displayed in the dot plots, the spontaneous cell death (Annexin V PE positive/7ADD negative, Annexin V PE positive/7ADD positive and Annexin V PE negative/7ADD positive cells) in cells cultured with the vehicle was approximately 7.5% in Raji-Ctrl and 5.5% in Raji-PCLP1 cells. (B) Expression of PCLP1 on Annexin V and 7ADD double-negative population of cells treated with dexamethasone or vehicle by flow cytometry. (C) Raji-Ctrl and Raji-PCLP1 cells were treated with increasing concentrations of vehicle or H2O2 for 6 h and cell death was analyzed as indicated in A. The graph on the left shows the mean percentages ± SD of total cell death from five independent experiments after subtracting the spontaneous cell death (vehicle). Representative dot plots showing Annexin V/7AAD staining in cells treated with vehicle or 200 µM H2O2 are shown (left). As displayed in the dot plots, the spontaneous cell death in the presence of vehicle was approximately 17.0% in Raji-Ctrl and 5.9% in Raji-PCLP1 cells. (D) Cells were incubated overnight with increasing concentrations of obinutuzumab or vehicle and cell viability was measured based on Annexin V/7AAD double negative staining relative to vehicle-treated cells. Data show the mean percentages ± SD of viable cells from six independent experiments. (E) A representative image of the homotypic adhesion induced by obinutuzumab as visualized by light microscopy is shown. The size bar indicates 100 µm. Statistical analysis was calculated using two-tailed paired Student´s t-test. *P < 0.05. **P < 0.01. ***P < 0.001.


Reference:

Product link:

PE Apoptosis Detection Kit

An article published this year in the “Clinical Immunology” using one of our products, “FITC Mouse Anti-Human CD56”, by our customers from Egypt, in the analysis of how Modulation the expression of natural killer cell activating receptor (NKp44) in the peripheral blood of diffuse large B-cell lymphoma patients and the correlation with clinic pathological features. Congrats and Thanks.


Summay:
NK cell activation is one strategy to improve the immunotherapy of non-Hodgkin's lymphoma. So, we aimed to investigate expression of Natural killer cell activating receptor NKp44 in patients with diffuse large B-cell lymphoma (DLBCL) and its correlation with clinic pathological data. In this study, 30 new cases with DLBCL in addition to 20 healthy control were involved. All were submitted to full history, clinical examination, histopathology, Routine laboratory investigations including CBC, LDH, β2microgloubine and bone marrow examination. Cell culture of peripheral blood mononuclear cells and expression of CD56 and NKp44 by flowcytometry was done. We demonstrated increased NK cell populations (CD 56 + ve NKp44 –ve, CD 56 –veNKp44 + ve, total CD 56 + ve) and NKp44 MFI after in-vitro activation in both healthy control and DLBCL cases except for CD 56 + ve NKp44 + ve which significantly increased in patients not in healthy control (p = 0.005, 0.601) respectively. No significant difference between the DLBCL and healthy control regarding all NK cell populations without PHA stimulation. However, the culture with PHA in DLBCL showed significant increase in NK cell populations than the healthy control (CD 56 + ve NKp44 + ve 12.37 ± 7.52vs 6.80 ± 4.07, p = 0.008), (Total CD 56 + ve 18.80 ± 8.74vs 12.66 ± 5.17, p = 0.017), (MFI of NKp44 10.95 ± 6.18vs 5.58 ± 1.70, p = 0.001). Regarding the association with clinic pathologic features, increased expression of NKp44 was associated with lower values of LDH and earlier stages of DLBCL (p < 0.05). So, activating receptor NKp44 can be modulated by in-vitro activation, hence improvement of its function as an approach of immunotherapy of DLBCL.


a: flowcytometric analysis of CD56 and NKp44 expression in control without PHA stimulation. b: flowcytometric analysis of CD56 and NKp44 expression in control with PHA stimulation.


Reference:

Product link:

FITC Mouse anti-Human CD56

Monday 18 December 2017

An article published in “The University of Valladolid” using our FITC Mouse Anti-Human CD3 during their Final Master Degree Work by our customers from the IOBA, Valladolid, Spain, in the analysis of how ALTERATIONS OF THE IMMUNE SYSTEM OF THE OCULAR MUCOSA IN THE PEDIATRIC SEVERE OCULAR ALLERGY. Congrats and Thanks.


Summary:



The lymphoid tissue associated with the conjunctiva (CALT) is part of the system immune system of the ocular surface and provides a whole series of defense mechanisms for maintain its integrity. The immunotopographic distribution in healthy individuals can serve to deepen the knowledge of inflammatory pathologies of the ocular surface (OS), like allergic conjunctivitis. This preliminary work aims to initiate the same type of analysis in two serious diseases, of an inflammatory nature, with an allergic base important, atopic keratoconjunctivitis (QCA) and vernal keratoconjunctivitis (QCV). A day today, the diagnosis is clinical, being sometimes difficult the differential diagnosis of these two entities. This study could help to understand some aspects of its pathophysiology.





Reference:


Products link:

FITC Apoptosis Detection Kit

An article published in “Biochemical Pharmacology” using our FITC Apoptosis Detection Kit by our customers from the Istituto Nazionale dei Tumori, Italy, in the analysis of how FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Congrats and Thanks.


Summary:

The XPO1/CRM1 inhibitor selinexor (KPT-330), is currently being evaluated in multiple clinical trials as an anticancer agent. XPO1 participates in the nuclear export of FoxO-1, which we previously found to be decreased in platinum-resistant ovarian carcinoma. The aim of this study was to determine whether enriching FoxO-1 nuclear localization using selinexor would increase ovarian cancer cell sensitivity to cisplatin. Selinexor, as a single agent, displayed a striking antiproliferative effect in different ovarian carcinoma cell lines. A schedule-dependent synergistic effect of selinexor in combination with cisplatin was found in cisplatin-sensitive IGROV-1, the combination efficacy being more evident in sensitive than in the resistant cells. In IGROV-1 cells, the combination was more effective when selinexor followed cisplatin exposure. A modulation of proteins involved in apoptosis (p53, Bax) and in cell cycle progression (p21WAF1) was found by Western blotting. Selinexor-treated cells exhibited enriched FoxO-1 nuclear staining. Knock-down experiments with RNA interference indicated that FOXO1-silenced cells displayed a reduced sensitivity to selinexor. FOXO1 silencing also tended to reduce the efficacy of the drug combination at selected cisplatin concentrations. Selinexor significantly inhibited tumor growth, induced FoxO-1 nuclear localization and improved the efficacy of cisplatin in IGROV-1 xenografts. Taken together, our results support FoxO-1 as one of the key factors promoting sensitivity towards selinexor and the synergistic interaction between cisplatin and selinexor in ovarian carcinoma cells with selected molecular backgrounds, highlighting the need for treatment regimens tailored to the molecular tumor features.



Reference:


Products link:

FITC Apoptosis Detection Kit

An article published in “Stem Cell Research” using our Polyclonal Antibody Development Service by our customers from the, University of Extremadura, Spain, in the analysis of how Lung regeneration after toxic injury is improved in absence of dioxin receptor. Congrats and thanks.


Summary:

Recent experimental evidences from cellular systems and from mammalian and non-mammalian animal models highlight novel functions for the aryl hydrocarbon/dioxin receptor (AhR) in maintaining cell differentiation and tissue homeostasis. Notably, AhR depletion stimulates an undifferentiated and pluripotent phenotype likely associated to a mesenchymal transition in epithelial cells and to increased primary tumorigenesis and metastasis in melanoma. In this work, we have used a lung model of epithelial regeneration to investigate whether AhR regulates proper tissue repair by adjusting the expansion of undifferentiated stem-like cells. AhR-null mice developed a faster and more efficient repair of the lung bronchiolar epithelium upon naphthalene injury that required increased cell proliferation and the earlier activation of stem-like Clara, Basal and neuroepithelial cells precursors. Increased basal content in multipotent Sca1+/CD31−/CD4− cells and in cells expressing pluripotency factors NANOG and OCT4 could also improve re-epithelialization in AhR-null lungs. The reduced response of AhRdeficient lungs to Sonic Hedgehog (Shh) repression shortly after injury may also help their improved bronchiolar epithelium repair. These results support a role for AhR in the regenerative response against toxins, and open the possibility of modulating its activation level to favor recovery from lesions caused by environmental contaminants.

Reference:

Products link:

Custom Polyclonal Antibody Development Service


http://www.immunostep.com/content/27-monoclonal-and-polyclonal-antibody-development-service 

An article published in “Anticancer Research” using our FITC Apoptosis Detection Kit by our customers from the Wrocław University of Environmental and Life Sciences, Poland and  Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, in the analysis of how Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis. Congrats and Thanks.


Summary:

Targeting the extrinsic apoptotic pathway is an interesting option for anticancer therapy. A protein which such ability is Apo2 ligand, also known as TNF-related apoptosis-inducing ligand (TRAIL). The aim of this study was to examine the possibility of sensitizing resistant CLBL-1 canine lymphoma cells to TRAIL-induced apoptosis by using flavopiridol (FVP) a cyclin-dependent kinase inhibitor (CDKs). Materials and Methods: The CLBL-1 (canine B-cell lymphoma cell line) was used in the study. The effect of FVP and TRAIL treatment on apoptosis induction was assessed by flow cytometry and western blot. Results: Although canine lymphoma cells were resistant to TRAIL-induced apoptosis, combination of this death ligand with FVP was able to overcome TRAIL resistance of CLBL-1 lymphoma cells. Conclusion: Our results demonstrated that although canine lymphoma cells were resistant to TRAIL-induced apoptosis, combination of this death ligand with FVP was able to overcome TRAIL resistance of CLBL-1 lymphoma cell line. Although further investigation is required to deepen the knowledge of TRAIL as an antitumor agent in canine cancers, our results open the door to future use of TRAIL-based treatment strategies in veterinary oncology.

Reference:


Products link:
FITC Apoptosis Detection Kit